AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
When a PARP Inhibitor Works but the Body Cannot Tolerate It: Severe Niraparib Toxicity in BRCA1-Mutated Ovarian Cancer
By Loan Retchless, ARNP
Updated pooled analyses of niraparib maintenance trials continue to show a clear progression-free survival benefit, particularly in BRCA-mutated and HRD-positive ovarian cancer, without a corresponding overall survival advantage
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Safe Delivery of CAR-T and Bispecific Therapy: Managing CRS and Building the Infrastructure Behind It
By Justine Wilson-Miller, PharmD, BCOP
Centers manage cytokine release syndrome (CRS) very differently, and patient safety depends on the system, not only the drug.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
Financial Toxicity and Access to Oral Chemotherapy: Prior Authorization, Specialty Pharmacy Steering, and the Importance of Advocacy
By Sarah Profitt, PharmD, MMHC, BCOP
Prior authorization requirements and specialty pharmacy steering by payors delay the start of oral anticancer therapy, interrupt established treatment and worsen adherence.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
By Robert Samstein, MD, PhD
Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.
PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
By Robert Samstein, MD, PhD
Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.
PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
By Robert Samstein, MD, PhD
Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.
Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
By Munveer Bhangoo, MD
For more than two decades, cisplatin-based chemotherapy followed by radical cystectomy has been the standard approach to muscle-invasive bladder cancer (MIBC)
Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
By Munveer Bhangoo, MD
For more than two decades, cisplatin-based chemotherapy followed by radical cystectomy has been the standard approach to muscle-invasive bladder cancer (MIBC)
Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
By Munveer Bhangoo, MD
For more than two decades, cisplatin-based chemotherapy followed by radical cystectomy has been the standard approach to muscle-invasive bladder cancer (MIBC)